Cargando…
1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection
The outbreak of SARS-CoV-2 virus caused more than 80,155,187 confirmed COVID-19 cases worldwide, which has posed a serious threat to global public health and the economy. The development of vaccines and discovery of novel drugs for COVID-19 are urgently needed. Although the FDA-approved SARS-CoV-2 v...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058605/ https://www.ncbi.nlm.nih.gov/pubmed/33897423 http://dx.doi.org/10.3389/fphar.2021.634176 |
_version_ | 1783681046681747456 |
---|---|
author | Chen, Rui Hong Yang, Li Jun Hamdoun, Sami Chung, Sookja Kim Lam, Christopher Wai-kei Zhang, Kai Xi Guo, Xiaoling Xia, Chenglai Law, Betty Yuen Kwan Wong, Vincent Kam Wai |
author_facet | Chen, Rui Hong Yang, Li Jun Hamdoun, Sami Chung, Sookja Kim Lam, Christopher Wai-kei Zhang, Kai Xi Guo, Xiaoling Xia, Chenglai Law, Betty Yuen Kwan Wong, Vincent Kam Wai |
author_sort | Chen, Rui Hong |
collection | PubMed |
description | The outbreak of SARS-CoV-2 virus caused more than 80,155,187 confirmed COVID-19 cases worldwide, which has posed a serious threat to global public health and the economy. The development of vaccines and discovery of novel drugs for COVID-19 are urgently needed. Although the FDA-approved SARS-CoV-2 vaccines has been launched in many countries recently, the strength of safety, stringent storage condition and the possibly short-term immunized efficacy remain as the major challenges in the popularity and recognition of using vaccines against SARS-CoV-2. With the spike-receptor binding domain (RBD) of SARS-CoV-2 being responsible for binding to human angiotensin-converting enzyme 2 receptor (hACE2), ACE2 is identified as the receptor for the entry and viral infection of SARS-CoV-2. In this study, molecular docking and biolayer interferometry (BLI) binding assay were adopted to determine the direct molecular interactions between natural small-molecule, 1,2,3,4,6-Pentagalloyl glucose (PGG) and the spike-RBD of the SARS-CoV-2. Our results showed that PGG preferentially binds to a pocket that contains residues Glu 340 to Lys 356 of spike-RBD with a relatively low binding energy of -8 kcal/mol. BLI assay further confirmed that PGG exhibits a relatively strong binding affinity to SARS-CoV-2-RBD protein in comparison to hACE2. In addition, both ELISA and immunocytochemistry assay proved that PGG blocks SARS-CoV-2-RBD binding to hACE2 dose dependently in cellular level. Notably, PGG was confirmed to abolish the infectious property of RBD-pseudotyped lentivirus in hACE2 overexpressing HEK293 cells, which mimicked the entry of wild type SARS-CoV-2 virus in human host cells. Finally, maximal tolerated dose (MTD) studies revealed that up to 200 mg/kg/day of PGG was confirmed orally safe in mice. Our findings suggest that PGG may be a safe and potential antiviral agent against the COVID-19 by blockade the fusion of SARS-CoV-2 spike-RBD to hACE2 receptors. Therefore, PGG may be considered as a safe and natural antiviral agent for its possible preventive application in daily anti-virus hygienic products such as a disinfectant spray or face mask. |
format | Online Article Text |
id | pubmed-8058605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80586052021-04-22 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection Chen, Rui Hong Yang, Li Jun Hamdoun, Sami Chung, Sookja Kim Lam, Christopher Wai-kei Zhang, Kai Xi Guo, Xiaoling Xia, Chenglai Law, Betty Yuen Kwan Wong, Vincent Kam Wai Front Pharmacol Pharmacology The outbreak of SARS-CoV-2 virus caused more than 80,155,187 confirmed COVID-19 cases worldwide, which has posed a serious threat to global public health and the economy. The development of vaccines and discovery of novel drugs for COVID-19 are urgently needed. Although the FDA-approved SARS-CoV-2 vaccines has been launched in many countries recently, the strength of safety, stringent storage condition and the possibly short-term immunized efficacy remain as the major challenges in the popularity and recognition of using vaccines against SARS-CoV-2. With the spike-receptor binding domain (RBD) of SARS-CoV-2 being responsible for binding to human angiotensin-converting enzyme 2 receptor (hACE2), ACE2 is identified as the receptor for the entry and viral infection of SARS-CoV-2. In this study, molecular docking and biolayer interferometry (BLI) binding assay were adopted to determine the direct molecular interactions between natural small-molecule, 1,2,3,4,6-Pentagalloyl glucose (PGG) and the spike-RBD of the SARS-CoV-2. Our results showed that PGG preferentially binds to a pocket that contains residues Glu 340 to Lys 356 of spike-RBD with a relatively low binding energy of -8 kcal/mol. BLI assay further confirmed that PGG exhibits a relatively strong binding affinity to SARS-CoV-2-RBD protein in comparison to hACE2. In addition, both ELISA and immunocytochemistry assay proved that PGG blocks SARS-CoV-2-RBD binding to hACE2 dose dependently in cellular level. Notably, PGG was confirmed to abolish the infectious property of RBD-pseudotyped lentivirus in hACE2 overexpressing HEK293 cells, which mimicked the entry of wild type SARS-CoV-2 virus in human host cells. Finally, maximal tolerated dose (MTD) studies revealed that up to 200 mg/kg/day of PGG was confirmed orally safe in mice. Our findings suggest that PGG may be a safe and potential antiviral agent against the COVID-19 by blockade the fusion of SARS-CoV-2 spike-RBD to hACE2 receptors. Therefore, PGG may be considered as a safe and natural antiviral agent for its possible preventive application in daily anti-virus hygienic products such as a disinfectant spray or face mask. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC8058605/ /pubmed/33897423 http://dx.doi.org/10.3389/fphar.2021.634176 Text en Copyright © 2021 Chen, Yang, Hamdoun, Chung, Lam, Zhang, Guo, Xia, Law and Wong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Rui Hong Yang, Li Jun Hamdoun, Sami Chung, Sookja Kim Lam, Christopher Wai-kei Zhang, Kai Xi Guo, Xiaoling Xia, Chenglai Law, Betty Yuen Kwan Wong, Vincent Kam Wai 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection |
title | 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection |
title_full | 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection |
title_fullStr | 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection |
title_full_unstemmed | 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection |
title_short | 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection |
title_sort | 1,2,3,4,6-pentagalloyl glucose, a rbd-ace2 binding inhibitor to prevent sars-cov-2 infection |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058605/ https://www.ncbi.nlm.nih.gov/pubmed/33897423 http://dx.doi.org/10.3389/fphar.2021.634176 |
work_keys_str_mv | AT chenruihong 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT yanglijun 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT hamdounsami 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT chungsookjakim 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT lamchristopherwaikei 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT zhangkaixi 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT guoxiaoling 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT xiachenglai 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT lawbettyyuenkwan 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection AT wongvincentkamwai 12346pentagalloylglucosearbdace2bindinginhibitortopreventsarscov2infection |